{"id":1382,"date":"2025-08-14T04:00:22","date_gmt":"2025-08-14T04:00:22","guid":{"rendered":"https:\/\/www.inbody.in\/blog\/?p=1382"},"modified":"2026-04-23T05:00:09","modified_gmt":"2026-04-23T05:00:09","slug":"glim-criteria-why-muscle-mass-beats-albumin-in-malnutrition-diagnosis","status":"publish","type":"post","link":"https:\/\/www.inbody.in\/blog\/glim-criteria-why-muscle-mass-beats-albumin-in-malnutrition-diagnosis","title":{"rendered":"GLIM Criteria: Why Muscle Mass Beats Albumin in Malnutrition Diagnosis"},"content":{"rendered":"\n

Albumin: Important but Not Enough \u2013 The GLIM Shift<\/strong><\/p>\n\n\n\n

Serum albumin is widely used in Indian hospitals and public health programs to assess nutritional status. It helps identify patients who may need targeted nutrition therapy, especially in conditions like chronic kidney disease, cancer, or post-surgical recovery.<\/p>\n\n\n\n

However, albumin levels can sometimes be misleading. They are often lowered by inflammation, regardless of a person\u2019s actual nutritional reserves. Because of this, albumin is better understood as an inflammation marker (a \u201cnegative acute-phase reactant\u201d) rather than a true indicator of nutrition.<\/p>\n\n\n\n

Recognising this limitation, four major societies, ASPEN, ESPEN, FELANPE, and PENSA, introduced the Global Leadership Initiative on Malnutrition (GLIM) criteria in 2018. These guidelines emphasise the importance of measuring muscle mass alongside biochemical markers.<\/p>\n\n\n\n

Countries like Japan and France already include muscle mass assessment as a regular part of nutrition care. In India, combining muscle mass checks with serum albumin can provide a clearer and more accurate view of a patient\u2019s health.<\/p>\n\n\n\n

Ultimately, muscle mass matters. It reflects strength, supports recovery, and gives a better picture of overall health.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

<\/span>What Does GLIM Guidance Mean for Diagnosing Malnutrition?<\/strong><\/strong><\/strong><\/span><\/h2>\n\n\n\n

The Global Leadership Initiative on Malnutrition, better known as GLIM, came into existence in 2016.<\/a> It was the result of a joint effort between four major international clinical nutrition societies: ESPEN, ASPEN, FELANPE, and PENSA. The goal was simple but ambitious: create a single, worldwide standard for defining and diagnosing malnutrition.<\/p>\n\n\n\n

Before this, nutritional assessment often depended on a clinician\u2019s personal judgment. Different countries used different benchmarks, which made research comparisons tricky and slowed down any coordinated global strategy. GLIM was designed to cut through this problem, and over the years, it has caught on. By February 2025, PubMed had listed more than 460 studies referencing the framework.<\/p>\n\n\n\n

GLIM works in three main stages. First, there\u2019s risk screening<\/strong>, spotting people who might be at risk. This can be done with any validated tool, such as the MUST or NRS-2002. If the person is flagged as \u201cat risk,\u201d the next step is a full diagnostic assessment<\/strong>, which looks at five specific criteria. These are split into two groups: three are phenotypic<\/em> (relating to body measurements and composition) and two are etiologic<\/em> (relating to underlying causes). To diagnose malnutrition, you need at least one from each category.<\/p>\n\n\n\n

Finally, there\u2019s severity grading<\/strong>, which is based only on the phenotypic measures. This last step is important because it not only confirms the problem but also helps guide how urgently and aggressively it should be treated.<\/p>\n\n\n\n

<\/span>HOW TO USE THE GLIM FRAMEWORK<\/strong><\/strong><\/span><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

<\/span>Why Measuring Muscle Mass Using GLIM Is Often Challenging<\/strong><\/span><\/h2>\n\n\n\n

When the GLIM criteria were first introduced, they gave a strong overall framework for diagnosing malnutrition<\/a>. Earlier, there wasn\u2019t much clarity on how to measure muscle mass. It was also unclear what counts as \u201clow muscle mass.\u201d<\/p>\n\n\n\n

However,<\/strong> this changed in 2022. New guidelines added more practical details. They did not change the main ideas. Instead,<\/strong> they explained how to measure muscle mass and what numbers to use.<\/p>\n\n\n\n

In general,<\/strong> skeletal muscle mass is the best way to assess this. There are a few common methods. These include CT scans, DXA scans, and BIA devices. However,<\/strong> each method works in a different way. So,<\/strong> there is no single standard for everyone.<\/p>\n\n\n\n

The cutoffs also vary from person to person. For example,<\/strong> age, sex, and ethnicity all matter. Health conditions can also affect the results.<\/p>\n\n\n\n

When it comes to<\/strong> defining \u201clow muscle mass,\u201d experts suggest using existing guidelines. These include sarcopenia guidelines from European and Asian groups. In addition,<\/strong> they borrow ideas from bone health scores like T-scores and Z-scores. This helps keep results consistent.<\/p>\n\n\n\n

However,<\/strong> there is one important limitation. None of these tools directly measure muscle. They all estimate it in different ways. Because of this,<\/strong> the results are not always perfect.<\/p>\n\n\n\n

For instance,<\/strong> in people with obesity or high body water, results can be misleading. Extra fluid in the body can affect the readings. As a result,<\/strong> muscle mass may look higher than it actually is.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

<\/span>Frequently Asked Questions<\/span><\/h2>\n\n\n\n
\n

What are the GLIM criteria for malnutrition?<\/p><\/div>

<\/path><\/path><\/svg> <\/div>
<\/path><\/path><\/svg> <\/div><\/div><\/div>
\n

The Global Leadership Initiative on Malnutrition (GLIM) introduced an approach for malnutrition diagnosis in 2019 comprised of screening followed by assessment of three phenotypic criteria: weight loss, low BMI, and low muscle mass<\/strong>, and two etiologic criteria: reduced food intake\/assimilation, and inflammation\/disease.<\/p>\n<\/div><\/div>\n\n\n\n

How does malnutrition affect muscle mass?<\/p><\/div>

<\/path><\/path><\/svg> <\/div>
<\/path><\/path><\/svg> <\/div><\/div><\/div>
\n

Interestingly, malnutrition seems to be related to muscle health decline and may contribute to the development of sarcopenia [14,15,16] and aggravate the age-associated loss of muscle mass<\/strong>, muscle strength and physical performance [17,18].<\/p>\n<\/div><\/div>\n\n\n\n

What are the Glim criteria for critical care?<\/p><\/div>

<\/path><\/path><\/svg> <\/div>
<\/path><\/path><\/svg> <\/div><\/div><\/div>
\n

The GLIM criteria for diagnosing malnutrition include three phenotypic criteria: weight loss, low Body Mass Index (BMI), and reduced muscle mass<\/strong>, and two etiologic criteria: reduced food intake or assimilation and chronic and\/or acute inflammation.<\/p>\n<\/div><\/div>\n\n\n\n

What are the four indicators of malnutrition?<\/p><\/div>

<\/path><\/path><\/svg> <\/div>
<\/path><\/path><\/svg> <\/div><\/div><\/div>
\n

Common signs and symptoms of malnutrition include:<\/strong><\/p>\n\n\n\n

reduced ability to perform everyday tasks like showering, getting dressed or cooking. Loss of appetite and lack of interest in food or fluids. Unplanned weight loss \u2013 this might cause clothing, rings, watches or dentures to become loose.<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

<\/span>How BWA Technology Fills Gaps in GLIM Muscle Mass Assessment<\/strong><\/span><\/h2>\n\n\n\n

How InBody Measures Muscle Mass<\/strong><\/p>\n\n\n\n

You see, InBody checks muscle mass using something called Bioelectrical Impedance Analysis (BIA). What\u2019s great about this method is that, unlike CT or DXA scans, it involves no radiation at all<\/strong>. Because of this, it is completely safe, even if you need frequent testing.<\/p>\n\n\n\n

The process itself is very simple. A small, harmless electrical signal passes through your body, and you don\u2019t feel anything. As a result,<\/strong> the test is quick and comfortable. In fact, the entire process takes just a few minutes, making it ideal for regularly tracking your nutrition and muscle health.<\/p>\n\n\n\n

<\/span>Why InBody BWA Stands Out<\/span><\/h3>\n\n\n\n

InBody\u2019s Body Water Analyzer (BWA) is a top-tier medical device<\/strong>. Moreover, it is designed to address many of the gaps highlighted in the GLIM guidelines. It provides detailed readings that help healthcare professionals measure muscle mass more accurately. In addition,<\/strong> it helps them set practical and realistic cutoff points for better diagnosis.<\/p>\n\n\n\n

<\/span>Advanced Technology Behind BWA<\/span><\/h3>\n\n\n\n

The BWA is the first device in the world to use a 3 MHz high-frequency current. This was once considered difficult to achieve. Because of this advancement, the device can clearly distinguish between extracellular and intracellular water.<\/p>\n\n\n\n

Furthermore, it estimates Z\u2080 and Z\u221e, which are important values used in both clinical practice and research. As a result, healthcare professionals can better evaluate fluid overload in patients with oedema. At the same time, these insights also improve the accuracy of muscle mass measurements.<\/p>\n\n\n\n

<\/span>How BWA Overcame the Limitations Highlighted in GLIM Guidance<\/span><\/h3>\n\n\n\n

In addition, the BWA provides age-specific assessments based on over 130 million InBody measurements gathered worldwide. These include T-scores, which compare a person\u2019s results to healthy young adults. It also includes age-matched Z-scores, which show how results differ from the average for a specific age group.<\/p>\n\n\n\n

Because it focuses on analyzing body fluids, the BWA is especially valuable in key medical areas. These include fluid monitoring, diagnosing sarcopenia, and assessing cellular health.<\/p>\n\n\n\n

<\/span>BWA as a Promising Tool for Sarcopenia Diagnosis<\/span><\/h3>\n\n\n\n

One of the biggest advantages of the BWA is its growing use in diagnosing sarcopenia. It is now being used in both small clinics and large university hospitals.<\/p>\n\n\n\n

In 2021, Korea officially recognized sarcopenia as a medical condition. Since then, segmental multi-frequency BIA technology has proven effective in clinical settings. Although it is not yet reimbursed, many doctors are increasingly using InBody devices for regular screening.<\/p>\n\n\n\n

<\/span>Link Between Sarcopenia and Malnutrition<\/span><\/h3>\n\n\n\n

GLIM guidance also highlights that malnutrition often plays a key role in sarcopenia. Therefore, it recommends closely monitoring nutrition in affected patients.<\/p>\n\n\n\n

As this connection becomes clearer, more researchers are turning to BWA for body composition analysis. As a result, it is quickly becoming a trusted tool in both research and clinical practice.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n